Similarly, immune checkpoint inhibitors, such as anti-PD-1 and anti-CTLA-4 antibodies, have revolutionized melanoma treatment, but a substantial proportion of patients fail to respond or develop acquired resistance [22, 23]. Here, PDCD1 is linked to melanoma.